Hagar Labouta is an Assistant Professor at the College of Pharmacy, University of Manitoba (Canda) with research experience in nanomedicine, drug delivery, and biomedical engineering. She got her Ph.D. in pharmaceutical nanotechnology from Saarland University (Germany). She completed several Postdoctoral fellowships at Helmholtz institute (Germany), and Departments of Chemistry and Biomedical Engineering, University of Calgary (Canada). At University of Manitoba, her team is using microfluidic lab-on-a-chip models for designing and evaluating nanoparticles for the aim of breaching biological barriers such as the placenta and the extracellular matrix of a tumour. Her lab is well-funded by national (New Frontiers in Research Fund, NSERC) and international funds (New York Academy of Sciences, and Japan Agency for Medical Research and Development). Dr. Labouta has a strong publication record and is a co-inventor on an international patent for the development of nanosystems for intracellular targeting. She has also worked with the World Health Organization on two health-related projects. She has won several awards and fellowships including Innovation and Career Development Award by the Biomedical Engineering Society (USA), Apotheker Jacob Prize for the best PhD thesis (Germany), and DAAD Scholarship (Germany), and curriculum award for the Nanoscience Minor Program (Canada). She is a Young Associate Editor of Drug Delivery and Translational Research (DDTR), and an executive YSC committee member in the Controlled Release Society.